| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $1,913,052 | 15 | 100 |
| PETERS WILLIAM J | CFO, EVP & TREASURER | 0 | $0 | 1 | $116,515 | $-116,515 |
| PRINS RICHARD K | director | 0 | $0 | 2 | $550,955 | $-550,955 |
| Petersen Floyd F. | director | 0 | $0 | 10 | $572,767 | $-572,767 |
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER | 0 | $0 | 2 | $672,815 | $-672,815 |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Over the last 12 months, insiders at Amphastar Pharmaceuticals, Inc. have bought $0 and sold $1.91M worth of Amphastar Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Amphastar Pharmaceuticals, Inc. have bought $0 and sold $13.01M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,000 shares for transaction amount of $40,520 was made by Maris David (director) on 2020‑08‑14.
| 2025-11-25 | Sale | PRINS RICHARD K | director | 4,179 0.0095% | $27.10 | $113,253 | +1.81% | |
| 2025-11-13 | Sale | Petersen Floyd F. | director | 16,679 0.0365% | $26.49 | $441,837 | -1.79% | |
| 2025-11-03 | Sale | Petersen Floyd F. | director | 500 0.0011% | $25.27 | $12,633 | +4.65% | |
| 2025-10-01 | Sale | Petersen Floyd F. | director | 500 0.0011% | $27.20 | $13,602 | -5.26% | |
| 2025-09-02 | Sale | Petersen Floyd F. | director | 500 0.0011% | $30.98 | $15,492 | -13.84% | |
| 2025-08-01 | Sale | Petersen Floyd F. | director | 500 0.0011% | $20.83 | $10,416 | +26.59% | |
| 2025-07-02 | Sale | Petersen Floyd F. | director | 500 0.0011% | $23.47 | $11,734 | +10.60% | |
| 2025-06-02 | Sale | Petersen Floyd F. | director | 500 0.0011% | $25.67 | $12,835 | +1.89% | |
| 2025-05-01 | Sale | Petersen Floyd F. | director | 500 0.0011% | $24.08 | $12,041 | +6.20% | |
| 2025-04-01 | Sale | Petersen Floyd F. | director | 500 0.0011% | $28.38 | $14,190 | -10.82% | |
| 2025-03-06 | Sale | Petersen Floyd F. | director | 1,000 0.0021% | $27.99 | $27,986 | -9.89% | |
| 2025-03-04 | Sale | PETERS WILLIAM J | CFO, EVP & TREASURER | 4,231 0.0088% | $27.54 | $116,515 | -7.57% | |
| 2024-12-13 | Sale | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | 8,000 0.018% | $45.23 | $361,840 | -37.00% | |
| 2024-12-12 | Sale | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | 7,000 0.0145% | $44.42 | $310,975 | -40.19% | |
| 2024-12-09 | Sale | PRINS RICHARD K | director | 10,000 0.0207% | $43.77 | $437,702 | -39.26% | |
| 2024-11-12 | Sale | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | 6,893 0.0147% | $48.88 | $336,930 | -43.43% | |
| 2024-11-12 | Sale | PRINS RICHARD K | director | 5,000 0.0107% | $48.80 | $243,986 | -43.43% | |
| 2024-11-06 | Sale | PETERS WILLIAM J | CFO, EVP & TREASURER | 7,426 0.0148% | $52.05 | $386,523 | -48.79% | |
| 2024-11-06 | Sale | Liawatidewi Yakob | EVP CORP ADMIN CENTER | 5,214 0.0104% | $52.05 | $271,389 | -48.79% | |
| 2024-09-13 | Sale | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | 3,000 0.0062% | $48.26 | $144,785 | -37.97% |
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER | 118469 0.2578% | $3.22M | 0 | 33 | |
| PETERS WILLIAM J | CFO, EVP & TREASURER | 97363 0.2119% | $2.64M | 0 | 55 | |
| Petersen Floyd F. | director | 75531 0.1644% | $2.05M | 1 | 69 | +27.09% |
| PRINS RICHARD K | director | 35183 0.0766% | $955,218.45 | 2 | 43 | +28.12% |
| Applied Physics & Chemistry Laboratories, Inc. | 10 percent owner | 7327679 15.9463% | $198.95M | 0 | 11 | |
| Zhang Jack Y. | CEO & Chief Scientific Officer | 6827679 14.8582% | $185.37M | 2 | 35 | +24.35% |
| Luo Mary Z. | COO,Chief Scientist & Chairman | 1104416 2.4034% | $29.98M | 0 | 6 | |
| Koo Richard | director | 253270 0.5512% | $6.88M | 1 | 3 | +27.09% |
| Lee Howard | director | 142939 0.3111% | $3.88M | 1 | 18 | +18.46% |
| Shandell Jason B. | President and General Counsel | 138898 0.3023% | $3.77M | 0 | 35 | |
| Liawatidewi Yakob | EVP CORP ADMIN CENTER | 74938 0.1631% | $2.03M | 0 | 32 | |
| Purchase Marilyn J. | Corp. Exec. VP of Operations | 44902 0.0977% | $1.22M | 0 | 1 | |
| Shohet Stephen B. | director | 30706 0.0668% | $833,667.90 | 1 | 17 | +27.09% |
| ZASLOFF MICHAEL A | director | 21326 0.0464% | $579,000.90 | 1 | 18 | +29.92% |
| Maris David | director | 13151 0.0286% | $357,049.65 | 1 | 0 | <0.0001% |
| Gerst Diane G. | 12842 0.0279% | $348,660.30 | 0 | 19 | ||
| Deflin Gayle | director | 2716 0.0059% | $73,739.40 | 0 | 3 |
$910,099,463 | 123 | 11.52% | $2.73B | |
$12,681,496 | 70 | 20.90% | $2.07B | |
$218,350,131 | 64 | 16.68% | $748.64M | |
$14,599,168 | 59 | 12.79% | $1.86B | |
$129,489,279 | 57 | 26.09% | $624.41M | |
$102,709,455 | 46 | 30.55% | $1.09B | |
$11,542,910 | 40 | 56.19% | $1.73B | |
$73,312,053 | 38 | -4.37% | $1.86B | |
$21,068,600 | 35 | 9.64% | $1.29B | |
$6,021,989 | 30 | -0.17% | $639.53M | |
$6,506,230 | 27 | -16.20% | $953.62M | |
$25,034,841 | 20 | 9.38% | $606.79M | |
$83,406,412 | 19 | 21.96% | $2.52B | |
Amphastar Pharmaceuticals, Inc. (AMPH) | $1,843,996 | 10 | 22.92% | $1.25B |
$1,718,514 | 9 | 38.12% | $808.48M | |
$26,633,903 | 9 | 42.23% | $1.5B | |
$179,515 | 7 | 1.51% | $650.67M | |
$543,932 | 6 | -22.02% | $683.4M | |
$614,633 | 6 | 27.88% | $1.65B |
| Increased Positions | 121 | +40.6% | 4M | +10.92% |
| Decreased Positions | 132 | -44.3% | 4M | -11.7% |
| New Positions | 36 | New | 980,471 | New |
| Sold Out Positions | 39 | Sold Out | 1M | Sold Out |
| Total Postitions | 287 | -3.69% | 33M | -0.78% |
| Blackrock, Inc. | $151,936.00 | 11.92% | 5.49M | -183,736 | -3.24% | 2025-09-30 |
| Vanguard Group Inc | $72,880.00 | 5.72% | 2.63M | -55,910 | -2.08% | 2025-09-30 |
| Td Asset Management Inc | $53,513.00 | 4.2% | 1.93M | -103,038 | -5.06% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $48,632.00 | 3.82% | 1.76M | +128,781 | +7.92% | 2025-09-30 |
| State Street Corp | $41,571.00 | 3.26% | 1.5M | -75,491 | -4.79% | 2025-09-30 |
| Fuller & Thaler Asset Management, Inc. | $37,504.00 | 2.94% | 1.35M | +90,155 | +7.13% | 2025-09-30 |
| Boston Trust Walden Corp | $32,495.00 | 2.55% | 1.17M | -3,346 | -0.28% | 2025-09-30 |
| Epoch Investment Partners, Inc. | $31,411.00 | 2.47% | 1.13M | -107,383 | -8.65% | 2025-09-30 |
| Geode Capital Management, Llc | $25,555.00 | 2.01% | 922,577 | -50,660 | -5.21% | 2025-09-30 |
| Marshall Wace, Llp | $24,212.00 | 1.9% | 874,068 | +25,383 | +2.99% | 2025-09-30 |